방사선종양학

본문글자크기
  • 2025년 01월호
    [Urol J .] Prostate-Specific Antigen (PSA) Bounces Following Stereotactic Body Radiotherapy for Prostate Cancer: Importance of PSA Test Frequency

    가톨릭의대 / 강기문, 송진호*

  • 출처
    Urol J .
  • 등재일
    2024 Nov 27
  • 저널이슈번호
    21(6):384-389. doi: 10.22037/uj.v21i.8119.
  • 내용

    바로가기  >

    Abstract
    Purpose: Prostate-specific antigen (PSA) bounce is a common phenomenon that can be observed in patients of prostate cancer treated by radiotherapy. However, the clinical, pathological, or dosimetric predictors and clinical significance of PSA bounce in stereotactic body radiotherapy (SBRT) patients is still unknown.

    Methods: Between August 2006 to December 2015, 74 prostate cancer patients were treated by SBRT with Cyberknife at two medical centers. The prescription dose was 35-37.5 Gy in 5 fractions. Follow-up PSA tests were more frequently performed in one hospital than the other (median 4 vs. 10 times for initial one year). PSA bounce was defined as a rise of 0.2 ng/mL followed by a decline to or below the previous nadir.

    Results: A total of 74 patients, PSA bounce was observed in 41 patients (55.4%). On univariate analysis, the treated medical center (p = 0.02), PSA follow-up frequency (p = 0.01), patient age (p < 0.01), and total prescription dose (p = 0.03) were significant clinical factors in predicting the incidence of PSA bounce, while in multivariable analysis only the PSA follow-up frequency, and patient age remains significant.

    Conclusion: PSA bounce was seen in a significant proportion of patients after Cyberknife SBRT. The PSA follow- up test frequency, and patient age were significant factors that were correlated with the incidence of PSA bounces in this study.

     

     

    Affiliations

    Ki Mun Kang 1, Hun Sik Choi 2, Hong Seok Jang 3, Jin-Ho Song 4
    1Department of Radiation Oncology, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea. jsk92@gnu.ac.kr.
    2Department of Radiation Oncology, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea. hoonsil00@hanmail.net.
    3Department of Radiation Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. hsjang11@catholic.ac.kr.
    4Department of Radiation Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. cowtree@catholic.ac.kr.

     

  • 편집위원

    전립선암에서 전립선특이항원(PSA)은 치료 효과 및 재발을 예측하는데 매우 중요한 바이오마커입니다. 전립선암의 방사선치료를 시행했을 때 경우에 따라 PSA가 일시적인 상승(PSA bounce)을 보이는 경우가 종종 있는데, 본 연구는 전립선암 환자의 정위체부방사선치료(SBRT) 후 PSA bounce가 나타나는 예측인자와 임상적 의의를 후향적으로 분석했습니다. 총 74명의 환자 중 41명의 환자에서 PSA bounce가 나타났고, 다변량분석에서 환자의 연령(70세 이상 vs 70세 미만)과 PSA 검사 간격(연간 8회 이상 vs 8회 미만)이 유의한 인자로 보고 했습니다. 전립선암의 SBRT 후 환자의 연령이 적을수록, PSA 검사를 자주 할수록 PSA bounce가 더 나타날 수 있다는 점을 염두에 두어야 하겠다는 임상적 의의가 있어 보입니다.

    덧글달기2025-01-03 17:29:22

  • 덧글달기
    덧글달기
       IP : 18.97.9.170

    등록